StockMarketWire.com - IXICO said Wednesday it has signed an extension to an existing contract with a top 15 global pharmaceutical company for advanced imaging clinical trial services in a neurodegenerative disease, progressive supranuclear palsy.

The firm said the total contract value had increased from $1.2m to $1.95m and the project duration had been extended from 2019 into early 2020.

The contract extension reflected an expansion of the work to be performed amid an increase in the number of trial participants, sites and countries that were not included in the original scope of work.

Giulio Cerroni, Chief Executive Officer of IXICO, said: 'We have been working with this client since 2016 and are pleased to announce this project extension. This reflects our strategy to grow and expand our existing relationships with pharmaceutical clients industry and also demonstrates our capabilities in multi-centre clinical trials in rare neurodegenerative diseases.'

Story provided by StockMarketWire.com